EX02 CAR-T Cells for Relapsed and Refractory Acute Myeloid Leukemia

This trial is testing a new type of CAR-T cell therapy (called EX02 CAR-T) for people with acute myeloid leukemia (AML) that has come back or has not responded to standard chemotherapy. CAR-T therapy involves modifying a patient's own immune cells to target and attack leukemia cells. **You may be eligible if...** - You are between 18 and 70 years old - You have been diagnosed with AML that has relapsed or has not responded to standard treatment - Your leukemia cells test positive for the EX02 target protein - Your blood counts and organ function are within acceptable ranges - Your general health status is adequate (ECOG 0-2) **You may NOT be eligible if...** - You have active hepatitis A, B, C, or HIV - You have significant heart problems (heart failure, recent heart attack, or dangerous arrhythmias) - You are pregnant or breastfeeding - You have severe liver or kidney dysfunction - You have had a stem cell transplant and have not been off immunosuppressants for at least 6 weeks Talk to your doctor to see if this trial is right for you.